Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

NCT04940052 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Differentiated Thyroid Cancer (DTC)

Interventions

DRUG: Dabrafenib
DRUG: Trametinib
DRUG: Trametinib Placebo
DRUG: Dabrafenib placebo

Sponsor

Novartis Pharmaceuticals